| Title |
Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients Results of the OCEAN Trial
|
|---|---|
| Published in |
JACC: Heart Failure, August 2018
|
| DOI | 10.1016/j.jchf.2018.03.011 |
| Pubmed ID | |
| Authors |
Wei Jiang, David J. Whellan, Kirkwood F. Adams, Michael A. Babyak, Stephen H. Boyle, Jennifer L. Wilson, Chetan B. Patel, Joseph G. Rogers, William S. Harris, Christopher M. O’Connor |
| Abstract |
The goal of this study was to test the effects of long-chain omega-3 fatty acid supplementation on omega-3 levels, depressive symptoms, and other psychosocial factors, as well as other chronic heart failure (CHF)-related functional measures. Patients with CHF and depression had low blood omega-3 concentrations that were associated with an elevated risk of mortality. This study was a randomized, double-blind, placebo-controlled pilot clinical trial using a 400/200 eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) fish oil at 2 g and an almost pure EPA at 2 g, compared with a matched placebo, daily for 12 weeks for patients with CHF and major depressive disorder. Statistical analyses included the intention-to-treat population and "completers" (defined as participants consuming ≥70% of the capsules and completing the final endpoint evaluation between 10 and 14 weeks). A total of 108 patients with CHF and major depressive disorder and a score ≥18 on the Hamilton Depression Scale who were randomized at 1:1:1 to the 3 interventions at 3 enrolling centers from June 12, 2014, to May 19, 2016; 80 (74.1%) qualified as completers. Intention-to-treat analyses revealed that the levels of all omega-3 variables were significantly elevated in the omega-3 groups, whereas the placebo group showed little change; there were no between-group differences with overall depression measurements. Per-protocol exploratory analyses showed that scores on the social functioning measurement of the 36-item Short Form Health Survey improved notably in the 400/200 EPA/DHA (p = 0.040) and EPA (p = 0.10) groups compared with the placebo group. Spearman correlation analysis indicated that increased omega-3 indices were associated with improved cognitive depressive symptoms. Omega-3 supplementation resulted in significant increases in omega-3 levels in red blood cell counts, corresponding to a particular compound of omega-3. Changes in cognitive depressive symptoms and social function were in favor of the omega-3 supplementation. Further studies with larger sample sizes are necessary to confirm the benefits of omega-3 supplementation on modifying psychosocial factors for patients with CHF. (Omega-3 Supplementation for Co-Morbid Depression and Heart Failure Treatment [OCEAN]; NCT02057406). |
X Demographics
The data shown below were collected from the profiles of 23 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 9 | 39% |
| Spain | 2 | 9% |
| Nigeria | 1 | 4% |
| Canada | 1 | 4% |
| Turkey | 1 | 4% |
| Unknown | 9 | 39% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 57% |
| Scientists | 6 | 26% |
| Practitioners (doctors, other healthcare professionals) | 2 | 9% |
| Science communicators (journalists, bloggers, editors) | 2 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 143 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 143 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 29 | 20% |
| Student > Master | 14 | 10% |
| Researcher | 10 | 7% |
| Other | 7 | 5% |
| Student > Doctoral Student | 6 | 4% |
| Other | 18 | 13% |
| Unknown | 59 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 19% |
| Nursing and Health Professions | 14 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 6% |
| Agricultural and Biological Sciences | 6 | 4% |
| Psychology | 4 | 3% |
| Other | 17 | 12% |
| Unknown | 66 | 46% |
Attention Score in Context
This research output has an Altmetric Attention Score of 81. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 November 2019.
All research outputs
#527,233
of 25,385,509 outputs
Outputs from JACC: Heart Failure
#131
of 1,583 outputs
Outputs of similar age
#11,297
of 341,021 outputs
Outputs of similar age from JACC: Heart Failure
#3
of 29 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,583 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.2. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,021 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.